相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity
Dong-Gyun Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Small molecule tyrosine kinase inhibitors in glioblastoma
Gayoung Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
S. Park et al.
ANNALS OF ONCOLOGY (2020)
Discrepant glomerular filtration rate trends from creatinine and cystatin C in patients with chronic kidney disease: results from the KNOW-CKD cohort
Eunjeong Kang et al.
BMC NEPHROLOGY (2020)
rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects
Ji Min Kim et al.
CANCERS (2020)
Intraoperative frozen cytology of intraosseous cystic meningioma in the sphenoid bone
Na Rae Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea
Yoon Jin Cha et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
SMAD7 in keratinocytes promotes skin carcinogenesis by activating ATM-dependent DNA repair and an EGFR-mediated cell proliferation pathway
Huyen Trang Ha Thi et al.
CARCINOGENESIS (2019)
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
Vidyalakshmi Chandramohan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas
Hyungjin Kim et al.
THORACIC CANCER (2019)
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo et al.
CANCER RESEARCH AND TREATMENT (2019)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn et al.
LANCET ONCOLOGY (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park et al.
LANCET ONCOLOGY (2019)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Expression and clinical value of EGFR in human meningiomas
Magnus B. Arnli et al.
PEERJ (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Ji Yun Lee et al.
ONCOTARGET (2016)
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
Sun Min Lim et al.
ONCOTARGET (2016)
Experience with 7.0 T MRI in Patients with Supratentorial Meningiomas
Sang Woo Song et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2016)
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
Jin Ho Baek et al.
LUNG CANCER (2015)
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
Hyun Sun Woo et al.
INVESTIGATIONAL NEW DRUGS (2014)
Iatrogenic Cerebrospinal Fluid Oculorrhea
Mijung Chi et al.
JOURNAL OF CRANIOFACIAL SURGERY (2014)
Crush Cytology of Microcystic Meningioma with Extensive Sclerosis
Jae Yeon Seok et al.
Korean Journal of Pathology (2014)
Molecular pathologic diagnosis of epidermal growth factor receptor
Cecile L. Maire et al.
NEURO-ONCOLOGY (2014)
EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180
H. Feng et al.
ONCOGENE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Crush Cytology of a Primary Intraspinal Rhabdoid Papillary Meningioma: A Case Report
Juhyeon Jeong et al.
ACTA CYTOLOGICA (2013)
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma
Yasufumi Katanasaka et al.
MOLECULAR CANCER (2013)
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
Bryan D. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain
Angelique Guillaudeau et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas
Angelique Guillaudeau et al.
PLOS ONE (2012)
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Nicola Montano et al.
NEOPLASIA (2011)
Development of an EGFRvIII specific recombinant antibody
Puja Gupta et al.
BMC BIOTECHNOLOGY (2010)
Medical therapies for meningiomas
Patrick Y. Wen et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
Bryan D. Choi et al.
BRAIN PATHOLOGY (2009)
Genetically engineered T cells to target EGFRvIII expressing glioblastoma
Szofia S. Bullain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis
Na Rae Kim et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Erlotinib in non-small-cell lung cancer
Cesare Gridelli et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma
Jordi Bruna et al.
NEUROPATHOLOGY (2007)
Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients
Henriqueta A. C. Silva et al.
EUROPEAN JOURNAL OF CANCER (2006)
Epidemiology of intracranial meningioma
EB Claus et al.
NEUROSURGERY (2005)
The natural history of EGFR and EGFRvIII in glioblastoma patients
AB Heimberger et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
EGFR and EGFRvIII expression in primary breast cancer and cell lines
JM Rae et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas
U Andersson et al.
ACTA NEUROPATHOLOGICA (2004)
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance
KD Aldape et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2004)
Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis
H Ge et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
The WHO classification of tumors of the nervous system
P Kleihues et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
JS Smith et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
